
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a healthcare technology company specializing in diagnosing the source of lower back pain, boasting a vast addressable market opportunity of over $400 million per year in the US alone, with its novel and noninvasive Nociscan product. Recent clinical trial and commercialization efforts have been successful in adding new physicians and imaging centers, and the company's strong balance sheet with over $20 million in cash extends runway into FY2027. While risks to share price target remain, with positive growth in revenue and gross margin, Aclarion appears well-positioned for success.
Bears say
Aclarion is facing significant challenges with its revenue generation, as its Q4 FY25 revenues remained nominal despite an 81% increase. While scan volume for Nociscan also increased, the company's operating expenses were higher, resulting in a net loss per share higher than expectations. This pattern is expected to continue in FY25 and FY26, leading to a negative outlook for the company's financials.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares